Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGC Stock Forecast 2026-2027
$19.99
Current Price
$9.88B
Market Cap
Buy 9
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to RGC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
RGC Price Momentum
-16.4%
1 Week Change
-36.5%
1 Month Change
+10.7%
1 Year Change
-4.8%
Year-to-Date Change
-76.1%
From 52W High of $83.60
+112.9%
From 52W Low of $9.39
📊 TOP ANALYST CALLS
Did RGC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Regencell is one of their latest high-conviction picks.
Latest RGC Stock Price Targets & Analyst Predictions
RGC has shown a year-to-date change of -4.8% and a 1-year change of 10.7%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for RGC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGC Analyst Ratings
9
Buy
5
Hold
1
Sell
RGC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $19.99
Latest RGC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 6, 2017 | Macquarie | Chad Beynon | Neutral | Downgrade | $N/A |
| Dec 6, 2017 | MoffettNathanson | Robert Fishman | Neutral | Upgrade | $N/A |
| Dec 6, 2017 | RBC Capital | Leo Kulp | Sector Perform | Downgrade | $N/A |
| Dec 5, 2017 | Wedbush | Michael Pachter | Neutral | Downgrade | $N/A |
| Oct 26, 2017 | RBC Capital | Leo Kulp | Outperform | Upgrade | $N/A |
Regencell Bioscience Holdings Ltd. (RGC) Competitors
The following stocks are similar to Regencell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Regencell Bioscience Holdings Ltd. (RGC) Financial Data
Regencell Bioscience Holdings Ltd. has a market capitalization of $9.88B with a P/E ratio of -2,790.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -177.7%.
Valuation Metrics
Market Cap
$9.88B
Enterprise Value
$10.96B
P/E Ratio
-2,790.3x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.0%
Current Ratio
1.4x
Debt/Equity
31.7x
ROE
-177.7%
ROA
-85.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Regencell Bioscience Holdings Ltd. (RGC) Business Model
About Regencell Bioscience Holdings Ltd.
What They Do
Develops Traditional Chinese Medicine formulations for neurocognitive disorders.
Business Model
The company focuses on researching, developing, and commercializing TCM formulations, primarily targeting conditions like ADHD and ASD. It generates revenue through the sale of its natural treatment products and may also receive funding for its community initiatives.
Additional Information
Regencell operates from Hong Kong and is involved in community support through the Regencell Foundation, which aids children with ADHD and ASD, as well as elderly individuals with dementia. This commitment to social responsibility enhances its reputation and aligns with its mission to improve healthcare through innovative TCM solutions.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
10
CEO
Mr. Yat-Gai Au
Country
Hong Kong
IPO Year
2021
Website
www.regencellbioscience.comRegencell Bioscience Holdings Ltd. (RGC) Latest News & Analysis
Latest News
Quick Summary
Regencell Bioscience Holdings Limited (NASDAQ: RGC) shareholders are urged to contact Gross Law Firm for potential lead plaintiff appointment concerning a class period.
Why It Matters
This notice indicates potential legal actions against Regencell Bioscience, which could affect stock performance and shareholder value, prompting investors to reassess their positions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Faruqi & Faruqi is investigating potential claims against Regencell Bioscience Holdings (NASDAQ: RGC) for investors who suffered losses between Oct 28, 2024, and Oct 31, 2025. Deadline: June 23, 2026.
Why It Matters
Pending legal action against Regencell could indicate significant financial risks and potential losses for investors, affecting stock performance and market perception.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
A class action has been filed for investors in Regencell Bioscience Holdings (NASDAQ: RGC) who purchased shares between October 28, 2024, and October 31, 2025. The company focuses on TCM for ADHD and ASD.
Why It Matters
The class action could impact Regencell's stock price and investor confidence, signaling potential legal risks and financial instability for the company’s future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Faruqi & Faruqi is investigating claims against Regencell Bioscience (NASDAQ: RGC) for investors who suffered losses between Oct 28, 2024, and Oct 31, 2025, with a lead plaintiff deadline of June 23, 2026.
Why It Matters
The investigation into Regencell and the class action deadline may signal potential legal risks, impacting stock performance and investor sentiment.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm alerts investors in Regencell Bioscience (NASDAQ: RGC) who bought securities from Oct 28, 2024, to Oct 31, 2025, of a June 23, 2026, lead plaintiff deadline for potential compensation.
Why It Matters
Upcoming legal actions involving Regencell Bioscience may affect stock prices. Investors could face compensation claims, impacting market sentiment and stock valuation.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Investors in Regencell Bioscience Holdings (NASDAQ: RGC) from October 28, 2024, to October 31, 2025, should note a June 23, 2026, deadline to file for potential compensation at no upfront cost.
Why It Matters
The deadline for lead plaintiff status in a securities class action against Regencell could affect investor claims and potential compensation, impacting stock sentiment and market behavior.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About RGC Stock
What is Regencell Bioscience Holdings Ltd.'s (RGC) stock forecast for 2026?
Analyst forecasts for Regencell Bioscience Holdings Ltd. (RGC) are not currently available. The stock is trading at $19.99.
Is RGC stock a good investment in 2026?
According to current analyst ratings, RGC has 9 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $19.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGC stock?
Price predictions from Wall Street analysts for RGC are not currently available. The stock is trading at $19.99.
What is Regencell Bioscience Holdings Ltd.'s business model?
The company focuses on researching, developing, and commercializing TCM formulations, primarily targeting conditions like ADHD and ASD. It generates revenue through the sale of its natural treatment products and may also receive funding for its community initiatives.
What is the highest forecasted price for RGC Regencell Bioscience Holdings Ltd.?
Price targets from Wall Street analysts for RGC are not currently available. The stock is trading at $19.99.
What is the lowest forecasted price for RGC Regencell Bioscience Holdings Ltd.?
Price targets from Wall Street analysts for RGC are not currently available. The stock is trading at $19.99.
What is the overall RGC consensus from analysts for Regencell Bioscience Holdings Ltd.?
The overall analyst consensus for RGC is bullish. Out of 4 Wall Street analysts, 9 rate it as Buy, 5 as Hold, and 1 as Sell.
How accurate are RGC stock price projections?
Stock price projections, including those for Regencell Bioscience Holdings Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 6:06 PM UTC